Global Vaccines Market Insights, Size and Growth Forecast To 2027

Global Vaccines Market by Type (Monovalent Vaccines and Multivalent Vaccines), By Technology (Conjugate Vaccines, Inactivated & Subunit Vaccines, Live Attenuated Vaccines, Recombinant Vaccines, and Toxoid Vaccines), By Disease Indication (Covid-19, Pneumococcal Disease, DTP, Influenza, HPV, Meningococcal Disease, Polio, Hepatitis, Rotavirus and Others), By Route of Administration (Intramuscular and Subcutaneous Administration and Oral Administration), By Patient Type (Pediatric Patients and Adult Patients), By Distribution Channel (Institutional Sales, Hospital Pharmacies, Retail Pharmacies and Others) and By Region (North America, Europe, Asia Pacific, South America, and Middle East & Africa)

Published: Dec-2020	Report ID: HLCA2050	Pages: 1 - 250	Formats^*:
Category : Healthcare

Global Vaccines market projected to trigger by the emerging vaccines for malaria, HIV, Ebola, dengue, etc., and the rising awareness about early disease diagnosis and prevention. Global Vaccines market likely to grow with a noteworthy rate during the forecast period, 2020-2027. It is primarily attributed to the surge in demand for better healthcare infrastructure and high awareness levels of the benefits of immunization. Moreover, the growing demand for vaccinations due to the rise in the incidence of both viral and bacterial infectious diseases are key factors expected to propel the growth of the vaccines market. Also, various governments' focus on immunization programs helps in creating awareness about safety. Additionally, the mounting of various companies' initiatives to augment vaccine research and development coupled with various organizations like WHO and the government support for vaccine development is estimated to accelerate the robust growth of the global vaccines market in the coming years. It is estimated that immunizations can prevent 2 to 3 million deaths from diphtheria, tetanus, pertussis, and measles each year.

With the general improvement of human living standards and the continuous increase of awareness of disease prevention, the global vaccine markets will continue to expand. The investment in vaccine research and development has gradually increased, and the research and development technology has gradually matured. The number and variety of new domestic vaccine products have continued to increase. According to WHO, immunization currently prevents 2-3 million deaths every year, and an estimated 19.4 million children are under the age of one year who did not receive essential vaccines. Also, WHO states that in 2018, about 116.3 million infants received three doses of diphtheria-tetanus-pertussis vaccines. WHO estimated that by 2018, 129 countries had reached at least 90% coverage of DTP3 vaccine.

Type Overview in the Global Vaccines market

Based on type, the global Vaccines market classified into Monovalent Vaccines and Multivalent Vaccines. The Monovalent Vaccines segment likely to gain maximum revenue by 2027, as it is used to place only one type of poliovirus circulates and reduced the risk of integration into the genome as compared to other traditional vaccines.

Technology Overview in the Global Vaccines market

Based on technology, the global Vaccine market segregated into Conjugate Vaccines, Inactivated & Subunit Vaccines, Live Attenuated Vaccines, Recombinant Vaccines, and Toxoid Vaccines. The Conjugate Vaccines segment accounted for the major share in 2019 for the vaccine market, due to their ability to elicit immunological memory and to reduce asymptomatic carriage of the bacteria, resulting in marked herd immunity.

Disease Indication Overview in the Global Vaccines market

Based on disease indication, the global vaccines market classified into Pneumococcal Disease, DTP, Influenza, HPV, Meningococcal Disease, Polio, Hepatitis, Rotavirus, and Others. The Pneumococcal Disease segment projected to lead the market attributable to the rising immunization concerns against a number of predominant pneumococcal diseases like middle ear infection, a blood infection, pneumonia, or bacterial meningitis.

Patient Type Overview in the Global Vaccines market

Based on patient type, the global Vaccines market bifurcates into Paediatric Patients and Adult Patients. The paediatric patient segments estimated to generate maximum revenue in the vaccine market by 2027. It is due to the surge in demand for infants, such as BCG vaccines, MMR vaccines, and DPT vaccines.

Distribution Channel Overview in the Global Vaccines market

Based on the distribution channel, the global Vaccines market categorized into Institutional Sales, Hospital Pharmacies, Retail Pharmacies, and Others. Institutional Sales segments are likely to lead the market by 2027 due to the various government's health organization aids in growing awareness regarding infectious diseases, especially for paediatrics.

Regional Overview in the Global Vaccines market

By geography, the Global Vaccines market segmented into North America, Europe, Asia Pacific, Middle East & Africa, and South America. North America accounted for a significant share in 2019. It will continue by 2027, owing to the surge in the healthcare expenditure, the presence of extensive research and development activities, and government initiatives.

Global Vaccines market: Competitive Landscape

Companies such as GlaxoSmithKline plc, Pfizer, Inc., Sanofi Pasteur, Merck & Co., Inc., CSL Limited, Emergent BioSolutions, Inc., Johnson & Johnson, AstraZeneca, Serum Institute of India Pvt. Ltd., Bavarian Nordic, Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo Company, Limited, Panacea Biotec, Biological E, Bharat Biotech, Sinovac Biotech Ltd., Incepta Vaccine Ltd., Valneva SE, VBI Vaccines Inc., and PT Bio Farma are the key players in the Global Vaccines Market.

1. Research Strategic Development

1.1. Market Modelling
1.2. Product Analysis
1.3. Market Trend and Economic Factors Analysis
1.4. Market Segmental Analysis
1.5. Geographical Mapping
1.6. Country Wise Segregation

2. Research Methodology

2.1. Identification of Target Market
2.2. Data Acquisition
2.3. Refining of Data/ Data Transformations
2.4. Data Validation through Primary Techniques
2.5. Exploratory Data Analysis
2.6. Graphical Techniques/Analysis
2.7. Quantitative Techniques/Analysis
2.8. Visual Result/Presentation

3. Executive Summary

4. Market Insights

4.1. Economic Factor Analysis
4.1.1. Drivers
4.1.2. Trends
4.1.3. Opportunities
4.1.4. Challenges
4.2. Technological Landscape
4.3. Competitors & Product Analysis
4.4. Regulatory Framework
4.5. Company market share analysis, 2019
4.6. Porterâ€™s Five forces analysis
4.7. New Investment Analysis
4.8. PESTEL Analysis

5. Global Vaccines Market Overview

5.1. Market Size & Forecast, 2016-2027
5.1.1. Demand
5.1.1.1. By Value (USD Million)
5.2. Market Share & Forecast, 2016-2027
5.2.1. By Type
5.2.1.1. Monovalent Vaccines
5.2.1.2. Multivalent Vaccines
5.2.2. By Technology
5.2.2.1. Conjugate Vaccines
5.2.2.2. Inactivated & Subunit Vaccines
5.2.2.3. Live Attenuated Vaccines
5.2.2.4. Recombinant Vaccines
5.2.2.5. Toxoid Vaccines
5.2.3. By Disease Indication
5.2.3.1. Covid-19
5.2.3.2. Pneumococcal Disease
5.2.3.3. DTP
5.2.3.4. Influenza
5.2.3.5. HPV
5.2.3.6. Meningococcal Disease
5.2.3.7. Polio
5.2.3.8. Hepatitis
5.2.3.9. Rotavirus
5.2.3.10. Others
5.2.4. By Route of Administration
5.2.4.1. Intramuscular and Subcutaneous Administration
5.2.4.2. Oral Administration
5.2.5. By Patient Type
5.2.5.1. Pediatric Patients
5.2.5.2. Adult Patients
5.2.6. By Distribution Channel
5.2.6.1. Institutional Sales
5.2.6.2. Hospital Pharmacies
5.2.6.3. Retail Pharmacies
5.2.6.4. Others
5.2.7. By Region
5.2.7.1. North America
5.2.7.2. Europe
5.2.7.3. Asia Pacific
5.2.7.4. South America
5.2.7.5. Middle East & Africa

6. North America Vaccines Market Overview

6.1. North America Vaccines Market Size & Forecast, 2016-2027
6.1.1. Demand
6.1.1.1. By Value (USD Million)
6.2. North America Vaccines Market Share & Forecast, 2016-2027
6.2.1. By Type
6.2.1.1. Monovalent Vaccines
6.2.1.2. Multivalent Vaccines
6.2.2. By Technology
6.2.2.1. Conjugate Vaccines
6.2.2.2. Inactivated & Subunit Vaccines
6.2.2.3. Live Attenuated Vaccines
6.2.2.4. Recombinant Vaccines
6.2.2.5. Toxoid Vaccines
6.2.3. By Disease Indication
6.2.3.1. Covid-19
6.2.3.2. Pneumococcal Disease
6.2.3.3. DTP
6.2.3.4. Influenza
6.2.3.5. HPV
6.2.3.6. Meningococcal Disease
6.2.3.7. Polio
6.2.3.8. Hepatitis
6.2.3.9. Rotavirus
6.2.3.10. Others
6.2.4. By Route of Administration
6.2.4.1. Intramuscular and Subcutaneous Administration
6.2.4.2. Oral Administration
6.2.5. By Patient Type
6.2.5.1. Pediatric Patients
6.2.5.2. Adult Patients
6.2.6. By Distribution Channel
6.2.6.1. Institutional Sales
6.2.6.2. Hospital Pharmacies
6.2.6.3. Retail Pharmacies
6.2.6.4. Others
6.2.7. By Country
6.2.7.1. US
6.2.7.2. Canada
6.2.7.3. Mexico
6.2.8. Price-Point Analysis
6.2.9. Manufacturer & Distributor List (Top 5)
6.2.10. Company Market Share (Top 3-5)
6.2.11. Economic Impact Study on North America Vaccines Market

7. Europe Vaccines Market Overview

7.1. Europe Vaccines Market Size & Forecast, 2016-2027
7.1.1. Demand
7.1.1.1. By Value (USD Million)
7.2. Europe Vaccines Market Share & Forecast, 2016-2027
7.2.1. By Type
7.2.1.1. Monovalent Vaccines
7.2.1.2. Multivalent Vaccines
7.2.2. By Technology
7.2.2.1. Conjugate Vaccines
7.2.2.2. Inactivated & Subunit Vaccines
7.2.2.3. Live Attenuated Vaccines
7.2.2.4. Recombinant Vaccines
7.2.2.5. Toxoid Vaccines
7.2.3. By Disease Indication
7.2.3.1. Covid-19
7.2.3.2. Pneumococcal Disease
7.2.3.3. DTP
7.2.3.4. Influenza
7.2.3.5. HPV
7.2.3.6. Meningococcal Disease
7.2.3.7. Polio
7.2.3.8. Hepatitis
7.2.3.9. Rotavirus
7.2.3.10. Others
7.2.4. By Route of Administration
7.2.4.1. Intramuscular and Subcutaneous Administration
7.2.4.2. Oral Administration
7.2.5. By Patient Type
7.2.5.1. Pediatric Patients
7.2.5.2. Adult Patients
7.2.6. By Distribution Channel
7.2.6.1. Institutional Sales
7.2.6.2. Hospital Pharmacies
7.2.6.3. Retail Pharmacies
7.2.6.4. Others
7.2.7. By Country
7.2.7.1. Germany
7.2.7.2. UK
7.2.7.3. France
7.2.7.4. Italy
7.2.7.5. Rest of Europe
7.2.8. Price-Point Analysis
7.2.9. Manufacturer & Distributor List (Top 5)
7.2.10. Company Market Share (Top 3-5)
7.2.11. Economic Impact Study on Europe Vaccines Market

8. Asia Pacific Vaccines Market Overview

8.1. Asia Pacific Vaccines Market Size & Forecast, 2016-2027
8.1.1. Demand
8.1.1.1. By Value (USD Million)
8.2. Asia Pacific Vaccines Market Share & Forecast, 2016-2027
8.2.1. By Type
8.2.1.1. Monovalent Vaccines
8.2.1.2. Multivalent Vaccines
8.2.2. By Technology
8.2.2.1. Conjugate Vaccines
8.2.2.2. Inactivated & Subunit Vaccines
8.2.2.3. Live Attenuated Vaccines
8.2.2.4. Recombinant Vaccines
8.2.2.5. Toxoid Vaccines
8.2.3. By Disease Indication
8.2.3.1. Covid-19
8.2.3.2. Pneumococcal Disease
8.2.3.3. DTP
8.2.3.4. Influenza
8.2.3.5. HPV
8.2.3.6. Meningococcal Disease
8.2.3.7. Polio
8.2.3.8. Hepatitis
8.2.3.9. Rotavirus
8.2.3.10. Others
8.2.4. By Route of Administration
8.2.4.1. Intramuscular and Subcutaneous Administration
8.2.4.2. Oral Administration
8.2.5. By Patient Type
8.2.5.1. Pediatric Patients
8.2.5.2. Adult Patients
8.2.6. By Distribution Channel
8.2.6.1. Institutional Sales
8.2.6.2. Hospital Pharmacies
8.2.6.3. Retail Pharmacies
8.2.6.4. Others
8.2.7. By Country
8.2.7.1. China
8.2.7.2. India
8.2.7.3. Japan
8.2.7.4. Australia
8.2.7.5. Rest of Asia Pacific
8.2.8. Price-Point Analysis
8.2.9. Manufacturer & Distributor List (Top 5)
8.2.10. Company Market Share (Top 3-5)
8.2.11. Economic Impact Study on Asia Pacific Vaccines Market

9. South America Vaccines Market Overview

9.1. South America Vaccines Market Size & Forecast, 2016-2027
9.1.1. Demand
9.1.1.1. By Value (USD Million)
9.2. South America Vaccines Market Share & Forecast, 2016-2027
9.2.1. By Type
9.2.1.1. Monovalent Vaccines
9.2.1.2. Multivalent Vaccines
9.2.2. By Technology
9.2.2.1. Conjugate Vaccines
9.2.2.2. Inactivated & Subunit Vaccines
9.2.2.3. Live Attenuated Vaccines
9.2.2.4. Recombinant Vaccines
9.2.2.5. Toxoid Vaccines
9.2.3. By Disease Indication
9.2.3.1. Covid-19
9.2.3.2. Pneumococcal Disease
9.2.3.3. DTP
9.2.3.4. Influenza
9.2.3.5. HPV
9.2.3.6. Meningococcal Disease
9.2.3.7. Polio
9.2.3.8. Hepatitis
9.2.3.9. Rotavirus
9.2.3.10. Others
9.2.4. By Route of Administration
9.2.4.1. Intramuscular and Subcutaneous Administration
9.2.4.2. Oral Administration
9.2.5. By Patient Type
9.2.5.1. Pediatric Patients
9.2.5.2. Adult Patients
9.2.6. By Distribution Channel
9.2.6.1. Institutional Sales
9.2.6.2. Hospital Pharmacies
9.2.6.3. Retail Pharmacies
9.2.6.4. Others
9.2.7. By Country
9.2.7.1. Brazil
9.2.7.2. Argentina
9.2.7.3. Rest of South America
9.2.8. Price-Point Analysis
9.2.9. Manufacturer & Distributor List (Top 5)
9.2.10. Company Market Share (Top 3-5)
9.2.11. Economic Impact Study on South America Vaccines Market

10. Middle East & Africa Vaccines Market Overview

10.1. Middle East & Africa Vaccines Market Size & Forecast, 2016-2027
10.1.1. Demand
10.1.1.1. By Value (USD Million)
10.2. Middle East & Africa Vaccines Market Share & Forecast, 2016-2027
10.2.1. By Type
10.2.1.1. Monovalent Vaccines
10.2.1.2. Multivalent Vaccines
10.2.2. By Technology
10.2.2.1. Conjugate Vaccines
10.2.2.2. Inactivated & Subunit Vaccines
10.2.2.3. Live Attenuated Vaccines
10.2.2.4. Recombinant Vaccines
10.2.2.5. Toxoid Vaccines
10.2.3. By Disease Indication
10.2.3.1. Covid-19
10.2.3.2. Pneumococcal Disease
10.2.3.3. DTP
10.2.3.4. Influenza
10.2.3.5. HPV
10.2.3.6. Meningococcal Disease
10.2.3.7. Polio
10.2.3.8. Hepatitis
10.2.3.9. Rotavirus
10.2.3.10. Others
10.2.4. By Route of Administration
10.2.4.1. Intramuscular and Subcutaneous Administration
10.2.4.2. Oral Administration
10.2.5. By Patient Type
10.2.5.1. Pediatric Patients
10.2.5.2. Adult Patients
10.2.6. By Distribution Channel
10.2.6.1. Institutional Sales
10.2.6.2. Hospital Pharmacies
10.2.6.3. Retail Pharmacies
10.2.6.4. Others
10.2.7. By Country
10.2.7.1. Saudi Arabia
10.2.7.2. UAE
10.2.7.3. South Africa
10.2.7.4. Rest of Middle East & Africa
10.2.8. Price-Point Analysis
10.2.9. Manufacturer & Distributor List (Top 5)
10.2.10. Company Market Share (Top 3-5)
10.2.11. Economic Impact Study on Middle East & Africa Vaccines Market

11. Competitor Analysis

11.1. Company Description
11.2. Financial Analysis
11.3. Key Products
11.4. Key Management Personnel
11.5. Contact Address
11.6. SWOT Analysis
11.7. Company Profile
11.7.1. GlaxoSmithKline plc
11.7.2. Pfizer, Inc.
11.7.3. Sanofi Pasteur
11.7.4. Merck & Co., Inc.
11.7.5. CSL Limited
11.7.6. Emergent BioSolutions, Inc.
11.7.7. Johnson & Johnson
11.7.8. AstraZeneca
11.7.9. Serum Institute of India Pvt. Ltd.
11.7.10. Bavarian Nordic
11.7.11. Mitsubishi Tanabe Pharma Corporation
11.7.12. Daiichi Sankyo Company, Limited
11.7.13. Panacea Biotec
11.7.14. Biological E Ltd
11.7.15. Bharat Biotech
11.7.16. Sinovac Biotech Ltd.
11.7.17. Incepta Vaccine Ltd.
11.7.18. Valneva SE
11.7.19. VBI Vaccines Inc.
11.7.20. PT Bio Farma
11.7.21. Other Prominent Players

SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.

The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.

SPER-Methodology-1